CRISPR-Cas9 Mouse Xenograft Study Shows ESR1 Mutations Facilitate Metastasis
Estrogen receptor gene (ESR1) mutations facilitate tumor metastasis.
Estrogen receptor gene (ESR1) mutations facilitate tumor metastasis.
Molecular tumor subtyping offers more accurate prediction of long-term breast cancer outcomes.
Adaptive randomization study finds neoadjuvant veliparib plus carboplatin may improve pCR in TNBC.
Patients with metastatic breast cancer did not benefit from switching to a second-line chemotherapy regimen after one cycle of first-line therapy.
Adding ramucirumab to docetaxel does not improve survival among patients with HER2-negative, advanced breast cancer.
Adding carboplatin or bevacizumab to standard chemotherapy improves pCR in TNBC.
Zoledronate does not improve survival rates among women with chemoresistant breast cancer.
Women with metastatic breast cancer who respond to chemotherapy should not receive locoregional treatment.
Reviews show a substantial reduction in breast cancer mortality with screening.
Some breast tumors resistance to chemotherapy and HER2-targeted therapy is associated with PIK3CA mutations.